Wolfgang Singer, M.D.

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and potential effectiveness of multiple doses of ONO-2808 in patients with MSA.  

The purpose of this study is to create biomarkers for parkinsonian disorders in CNS-originating extracellular vesicles.

The purpose of stiudy is to assess whether the fecal microbiomes of patients with progressive MSA exhibit deviations in microbial species composition, proteins, or metabolites as compared to healthy clinical controls, environmental controls, and a Parkinson’s disease comparison group.

The purpose of this study is to assess optimal dosing frequency, effectiveness and safety of adipose-derived autologous mesenchymal stem cells delivered into the spinal fluid of patients with multipe system atrophy (MSA).

Multiple system atrophy (MSA) is a rare, rapidly progressive, and invariably fatal neurological condition characterized by autonomic failure, parkinsonism, and/or ataxia. There is no available treatment to slow or halt disease progression. 

The goals of the study are to prospectively evaluate clinical and laboratory biomarkers of multiple system atrophy and Parkinson’s disease at early clinical disease, at a premotor stage (PAF), and even at a prodromal stage (RBD).

The purpose of this study is to evaluate the safety and effectiveness of TEV-56286, also known as ANLE138b, in adult patients with MSA ( Multiple System Atrophy).  

The purpose of this study is to develop a diagnostic test using tissue biomarkers to provide an accurate diagnosis of alpha-synucleinopathies in patients with Parkinson's disease, Multiple System Atrophy, Dementia with Lewy bodies and Pure Autonomic Failure. Using a simple diagnostic test will improve clinical accuracy in diagnosing, earlier diagnosis, and distinguishing between neurodegenerative diseases.

The purpose of this research study is to better understand what causes POTS. We believe that a number of different causes of POTS exist and that detailed testing can demonstrate the different causes. Knowing what causes POTS in a particular patient will be helpful in choosing the right treatment strategy for that particular patient in the future.

This research study is being done to develop better tests that can help physicians diagnose neurologic disorders earlier and with more certainty.

The purpose of this study is to evaluate the effectiveness of Lu AF82422 on disease progression in patients with Multiple System Atrophy (MSA).

The purpose of this study is to validate use of a modified Unified Multiple System Atrophy Rating Scale (UMSARS) that incorporates structured questions and additional instructions, developed by Biohaven Pharmaceuticals based on feedback from the FDA, as the primary outcome variable for assessing clinically meaningful change in Biohaven’s Phase 3 Multiple System Atrophy (MSA) Study BHV3241-301.

If the efficacy of 3,4-diaminopyridine (3,4-DAP) can be demonstrated in this study, the use of 3,4-DAP alone and in combination with other agents such as pyridostigmine and L-DOPS would be further evaluated in a double-blind randomized placebo-controlled cross-over study

The purpose of this study is to understand why patients with multiple system atrophy, Parkinson’s disease, Parkinson’s disease with autonomic failure, and dementia with Lewy bodies have a fall in blood pressure on standing up. It is believed that different patients develop these symptoms for different reasons. The reasons could be:

• damage to nerve supply to the legs

• the autonomic nerves are not working properly

• the brain is not controlling blood pressure or heart rate properly

This study will look at these different reasons.

The purpose of this research study is to better understand why patients with a disease that causes problems with the autonomic nervous system often have high blood pressure when they lie down. We hope that if we learn more about the cause for this problem, we will be able to treat the problem better in the future.

1. To evaluate whether SSRI use is associated with increased survival time and slower disease progression among patients with MSA.

2. To evaluate whether SSRI use is associated with the presence of clinical respiratory insufficiency such as stridor.